Apellis Pharms Company Profile
✉ Email this page to a colleague
What is the competitive landscape for APELLIS PHARMS, and when can generic versions of APELLIS PHARMS drugs launch?
APELLIS PHARMS has two approved drugs.
There are twelve US patents protecting APELLIS PHARMS drugs.
There are one hundred and fifty-three patent family members on APELLIS PHARMS drugs in twenty-five countries and eleven supplementary protection certificates in eleven countries.
Summary for Apellis Pharms
| International Patents: | 153 |
| US Patents: | 12 |
| Tradenames: | 2 |
| Ingredients: | 1 |
| NDAs: | 2 |
Drugs and US Patents for Apellis Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apellis Pharms | EMPAVELI | pegcetacoplan | SOLUTION;SUBCUTANEOUS | 215014-001 | May 14, 2021 | RX | Yes | Yes | 11,844,841 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Apellis Pharms | SYFOVRE | pegcetacoplan | SOLUTION;INTRAVITREAL | 217171-001 | Feb 17, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Apellis Pharms | SYFOVRE | pegcetacoplan | SOLUTION;INTRAVITREAL | 217171-001 | Feb 17, 2023 | RX | Yes | Yes | 8,168,584 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Apellis Pharms | SYFOVRE | pegcetacoplan | SOLUTION;INTRAVITREAL | 217171-001 | Feb 17, 2023 | RX | Yes | Yes | 9,056,076 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Apellis Pharms Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2007062249 | ⤷ Try a Trial |
| Lithuania | 3660033 | ⤷ Try a Trial |
| Canada | 2833202 | ⤷ Try a Trial |
| Japan | 6305382 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Apellis Pharms Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 3660033 | LUC00265 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: PEGCETACOPLAN; AUTHORISATION NUMBER AND DATE: EU/1/21/1595 20211214 |
| 3660033 | CA 2022 00023 | Denmark | ⤷ Try a Trial | PRODUCT NAME: PEGCETACOPLAN; REG. NO/DATE: EU/1/21/1595 20211214 |
| 3660033 | 2022017 | Norway | ⤷ Try a Trial | PRODUCT NAME: PEGCETACOPLAN; REG. NO/DATE: EU/1/21/1595 20211216 |
| 3660033 | 122022000034 | Germany | ⤷ Try a Trial | PRODUCT NAME: PEGCETACOPLAN; REGISTRATION NO/DATE: EU/1/21/1595 20211213 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
